Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH reduced its holdings in Charles River Laboratories by 41.2% in Q1, owning 11,419 shares valued at approximately $1.72 million.
• Various institutional investors, including American Century Companies and National Bank of Canada FI, have adjusted their stakes in Charles River Laboratories, with institutional ownership at 98.91%.
• Charles River Laboratories reported earnings of $2.34 per share for Q1, exceeding expectations, despite revenue declining 2.7% year-over-year.

Universal Beteiligungs und Servicegesellschaft mbH lessened its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 41.2% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 11,419 shares of the medical research company's stock after selling 7,991 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH's holdings in Charles River Laboratories International were worth $1,719,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Two Sigma Securities LLC raised its position in shares of Charles River Laboratories International by 4.3% during the fourth quarter. Two Sigma Securities LLC now owns 1,981 shares of the medical research company's stock valued at $366,000 after buying an additional 81 shares during the last quarter. Wahed Invest LLC raised its position in shares of Charles River Laboratories International by 6.5% during the fourth quarter. Wahed Invest LLC now owns 1,321 shares of the medical research company's stock valued at $244,000 after buying an additional 81 shares during the last quarter. Nomura Asset Management Co. Ltd. raised its position in shares of Charles River Laboratories International by 0.7% during the fourth quarter. Nomura Asset Management Co. Ltd. now owns 15,694 shares of the medical research company's stock valued at $2,897,000 after buying an additional 102 shares during the last quarter. Teachers Retirement System of The State of Kentucky raised its position in shares of Charles River Laboratories International by 2.7% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 3,916 shares of the medical research company's stock valued at $589,000 after buying an additional 102 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Charles River Laboratories International by 2.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,131 shares of the medical research company's stock valued at $763,000 after buying an additional 105 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company's stock.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the business's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the transaction, the executive vice president directly owned 19,513 shares in the company, valued at approximately $2,837,385.33. The trade was a 2.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.30% of the company's stock.

Charles River Laboratories International Stock Up 0.0%

Charles River Laboratories International stock traded up $0.01 during trading hours on Tuesday, reaching $167.93. The stock had a trading volume of 504,247 shares, compared to its average volume of 1,278,835. The company has a market cap of $8.25 billion, a price-to-earnings ratio of -258.00, a PEG ratio of 5.65 and a beta of 1.48. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.43 and a quick ratio of 1.16. The business's 50 day moving average price is $154.18 and its 200-day moving average price is $149.47. Charles River Laboratories International, Inc. has a 52 week low of $91.86 and a 52 week high of $234.90.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. The business had revenue of $984.17 million during the quarter, compared to the consensus estimate of $942.34 million. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The firm's revenue was down 2.7% on a year-over-year basis. During the same period in the previous year, the company posted $2.27 earnings per share. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Wall Street Analysts Forecast Growth

CRL has been the topic of several research reports. Cowen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating in a research report on Wednesday, May 14th. Wall Street Zen cut shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a research report on Saturday, July 5th. Barclays boosted their price target on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 8th. Evercore ISI boosted their price objective on shares of Charles River Laboratories International from $170.00 to $180.00 and gave the company an "outperform" rating in a research report on Wednesday, July 9th. Finally, Mizuho cut their price objective on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 9th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, Charles River Laboratories International has an average rating of "Hold" and a consensus price target of $174.54.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).